← All candidates
Five insider buys in the last year — $172.3K in all.
41 filings on record.
TNXPTonix Pharmaceuticals Holding Corp.
NasdaqGS · Healthcare · $199.29M
$11.62
-0.94% · Sep 15
Five insider buys in the last year — $172.3K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 5 buys◆ 32 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 8×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what TNXP ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$199.29M
Float
14.1M
82% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
6.8
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Executive Officer
Lederman Seth
Bought $58.9K on Jun 9 — 5,000 sh @ $11.79, held direct, 56% of their stake.
No completed positions to measure
Director
Stillwell Richard Newcomb
Bought $58.3K on Jun 8 — 5,000 sh @ $11.65, held direct, 100% of their stake.
First Form 4 on file
Director
Taylor Carolyn E.
Bought $15.1K on Aug 21 — 418 sh @ $36.03, held direct, 100% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
27 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
3 more transactions on Pro →Context
Wall St
$42.40 avg target
+264.9% vs today · 5 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 5 quarters beat
Q2 '26−$2.47 act+$0.15
Q1 '26−$2.93 act−$0.39
Q4 '25−$3.98 act−$1.04
Q3 '25−$3.59 act−$0.00
Coverage
Why Is TNXP Stock Rising Today?Stocktwits · 06-08Tonix prices 615,025 shares at $16.26 in registered direct offeringTipRanks · 12-30Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive NewsSimply Wall St. · 11-12Tonix Pharmaceuticals Holding Corp (TNXP) Showcases Promising TNX-801 Vaccine DataInsider Monkey · 10-29
The file stays open
41 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice